

Notice Regarding Adjustment of 340B Prices for Select Products of Astellas Pharma US, Inc.
04-06-2022

Astellas Pharma US, Inc. (Astellas) has recalculated its 340B ceiling prices for the period from Q3 2020 through Q2 2021 for the products listed below due to revisions made to reported Medicaid pricing data.

Astellas used chargeback data to identify Covered Entities that may be eligible for potential payment based on recalculated 340B ceiling prices, and to identify potential payment amounts to affected 340B Covered Entities. Astellas will be working through an external party to issue refunds. For Covered Entities that may be owed \$1,000 or more, refunds will be issued either to a Covered Entity's validated wholesaler pharmacy account when one can be identified, or a check will be issued to Covered Entities whose wholesaler account cannot be identified. For Covered Entities that may be owed less than \$1,000, and for Covered Entities that have questions regarding this 340B recalculation and refund process, please send an email to Dawn Powell at Dawn.Powell@astellas.com. Astellas is not seeking reimbursement or repayment where Covered Entities paid a lower price than the recalculated 340B ceiling prices for the specified quarters.

Astellas has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on OPA's public website to ensure transparency by providing access to information about Astellas's recalculation affecting certain 340B Covered Entities for the impacted products.

NDC	Product Description
00469-0125-99	Xtandi® 40MG Capsule
00469-0625-99	Xtandi® 40 MG Tablet
00469-0725-60	Xtandi® 80 MG Tablet
00469-2601-30	Myrbetriq® 25MG Tablet
00469-2601-90	Myrbetriq® 25MG Tablet
00469-2602-30	Myrbetriq® 50MG Tablet
00469-2602-90	Myrbetriq® 50MG Tablet